Welcome to the May 2018 edition of our Updates on Myeloproliferative Neoplasms (MPNs) newsletter. This month, we explore prognostication in MPNs, including three newer scoring systems and how genetics research is being incorporated into risk stratification. We also highlight an overview of investigational drugs in the MPN pipeline, as well as new research on the impact of anti-interferon-α antibodies on MPNs and the role of cytomegalovirus in the relapse of myeloproliferative disorders.
If you haven’t done so yet, check out our newest roundtable panel discussion, “Management of Myeloproliferative Neoplasms: A Case Based Discussion.” Three expert colleagues and I provide an overview of the current state of MPN treatment and management through three in-depth patient cases. You’ll get a front-row seat to insightful discussion and input on myelofibrosis, polycythemia vera (PV), and essential thrombocythemia (ET) from different perspectives within the health care team.
And don’t miss our new “fast facts” guides. These helpful and informative PDFs provide easy access to incidence and mortality data and World Health Organization diagnostic criteria for myelofibrosis, PV, and ET.
Please feel free to share this newsletter with your colleagues, and don’t hesitate to get in touch with me with comments or suggestions through the JADPRO editors at email@example.com at any time.
Lindsey Lyle, MS, PA-C
University of Colorado, Anschutz Medical Campus